LOS ANGELES--(BUSINESS WIRE)--AppliedVR has appointed Michael Marsau its Executive Director of Workers’ Compensation. He is overseeing the launch of the company’s flagship RelieVRx® prescription therapeutic into the workers’ compensation market. In this role, he develops and implements sales, marketing, and account service strategies for the AppliedVR’s workers’ comp channel and directs those efforts.
“Managing pain and avoiding addiction are major concerns for payors,” Marsau said. “I am very excited about introducing them to a non-pharmacological solution for chronic lower back pain.”
Marsau has held executive positions in workers’ compensation medical management companies for over 25 years, beginning with Cypress Care, an ancillary care provider that is now part of Optum. Most recently, he served as Vice President of Pharmacy Solutions for myMatrixx.
“The RelieVRx program is a game-changer for workers’ comp,” Marsau said. “This is a self-managed, home-based virtual reality therapeutic. It’s safe, cost-effective, clinically proven to reduce chronic lower back pain, and it continues to work after the injured worker completes the sessions.”
About AppliedVR
AppliedVR is creating a new reality in healthcare. We are pioneering immersive therapeutics (ITx), a new category of medicine, to treat intractable health conditions that affect millions of people around the world. By harnessing the unique properties of immersive therapeutics, we are developing a biopsychosocial solution to address biopsychosocial conditions such as chronic pain and behavioral and mental health disorders. Ultimately, we believe that everyone should have access to this transformative therapeutic and collectively, we are the catalyst of making this dream a shared reality.
Today, our virtual reality-based treatments represent a comprehensive approach to chronic pain that empowers patients with an intuitive device they can self-manage at home. AppliedVR’s RelieVRx is the first VR-based, prescription therapeutic to receive Breakthrough Therapy Designation and De Novo authorization by the FDA for chronic lower back pain (CLBP). CLBP affects 45 million people in the U.S. alone. We are poised to help millions more through our substantial development pipeline that addresses additional multi-dimensional conditions.
